Sanofi Finalizes Acquisition of Blueprint Medicines

Sanofi ( (SNY) ) has shared an update.

On July 18, 2025, Sanofi completed its acquisition of Blueprint Medicines Corporation, enhancing its portfolio with a commercialized medicine and a promising pipeline in systemic mastocytosis and other KIT-driven diseases. This acquisition strengthens Sanofi’s presence among allergists, dermatologists, and immunologists, and is expected to advance its immunology pipeline. The transaction, financed through cash and commercial paper issuances, is immediately accretive to gross margin and will positively impact business operating income and EPS after 2026. Blueprint’s shares will no longer be traded on NASDAQ following the merger.

The most recent analyst rating on (SNY) stock is a Buy with a $66.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.

Spark’s Take on SNY Stock

According to Spark, TipRanks’ AI Analyst, SNY is a Neutral.

Sanofi’s overall stock score reflects strong financial performance and positive earnings call highlights, including robust sales growth and strategic initiatives. However, technical analysis indicates bearish momentum, and cash flow weaknesses along with market uncertainties slightly temper the outlook.

To see Spark’s full report on SNY stock, click here.

More about Sanofi

Sanofi is a research and development-driven, AI-powered biopharmaceutical company focused on improving lives through innovative medicines and vaccines. With a strong emphasis on immunology, Sanofi aims to address urgent healthcare challenges and is listed on EURONEXT and NASDAQ.

Average Trading Volume: 2,300,301

Technical Sentiment Signal: Hold

Current Market Cap: $118B

See more insights into SNY stock on TipRanks’ Stock Analysis page.